

September 12, 2025

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra – Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that AstraZeneca Pharma India Limited (‘the Company’) has received a Show Cause Notice from National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India on September 11, 2025.

In this regard, please find the details as required under the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You

**For AstraZeneca Pharma India Limited**

Manasa R

Company Secretary

**Annexure – A**

Sl. No.	Particulars	Details
1.	Name of the opposing party	National Pharmaceutical Pricing Authority (NPPA)
2.	Brief details of dispute/litigation	NPPA, in its show cause notice dated September 11, 2025, has alleged that the Company has overcharged for batches of 'Symbicort Turbuhaler' Inhalation Powder, 60 Doses each, by marketing or manufacturing them at prices above the notified ceiling price subsequent to the relevant price notifications issued for the period from April 2016 to July 2025. The NPPA has given the Company 30 days to submit its response to these allegations.
3.	Court/tribunal/agency where the litigation is filed	Not Applicable
4.	Expected financial implications, if any, due to compensation, penalty etc.	The expected overall financial implication cannot be determined at this stage. The quantum of implication as per the notice is Rs. 60,49,79,385/- (Rupees Sixty Crore Forty Nine Lakh Seventy Nine Thousand Three Hundred and Eighty Five only) plus interest, which the Company disputes.
5.	Quantum of claims, if any	Rs. 60,49,79,385/- (Rupees Sixty Crore Forty Nine Lakh Seventy Nine Thousand Three Hundred and Eighty Five only) plus interest, which the Company disputes.